Philip Morris raises annual dividend to $6.40 per share
- Philip Morris raises quarterly dividend by 8.8% to $1.60 per share
- Annualized dividend reaches $6.40, payable October 26, 2026
- Smoke-free products contributed 42% of Q2FY26 net revenues
- Over 43 million legal-age consumers use PMI smoke-free products

*this image is generated using AI for illustrative purposes only.
Philip Morris International Inc. (NYSE: PM) has increased its regular quarterly dividend by 8.8% to an annualized rate of $6.40 per share. The new quarterly payout of $1.60, up from $1.47, is payable on October 26, 2026, to shareholders of record as of October 2, 2026.
The ex-dividend date is set for October 2, 2026. This increase continues the company’s long-standing commitment to returning capital to shareholders, with the dividend rising every year since the company went public in 2008.
Dividend Growth Trajectory
Since its initial public offering in 2008, Philip Morris has raised its annual dividend every year. This consistent growth represents a total increase of 248%, translating to a compound annual growth rate (CAGR) of 7.2%. The current hike maintains this trajectory, reinforcing the company’s position as a reliable income generator for investors.
Smoke-Free Portfolio Momentum
The dividend increase coincides with significant progress in the company’s transition toward a smoke-free future. As of December 31, 2025, PMI estimates that over 43 million legal-age consumers worldwide use its smoke-free products. Many of these users have moved away from cigarettes or significantly reduced their consumption.
Smoke-free products accounted for approximately 42% of the company’s total net revenues in the second quarter of 2026. The portfolio includes heat-not-burn devices, nicotine pouches, and e-vapor products, available in over 105 markets.
Regulatory and Scientific Milestones
Philip Morris has invested over $16 billion since 2008 to develop and scientifically substantiate its smoke-free offerings. These efforts have yielded key regulatory approvals from the U.S. Food and Drug Administration (FDA).
The FDA has authorized the marketing of Swedish Match’s General snus, ZYN nicotine pouches, and versions of PMI’s IQOS devices and consumables. These represent the first-ever such authorizations in their respective categories. Additionally, versions of IQOS, General snus, and 20 ZYN nicotine pouch variants received Modified Risk Tobacco Product authorizations from the FDA.
What the Numbers Show
The dividend growth rate of 8.8% significantly outpaces the long-term CAGR of 7.2% achieved since 2008. This acceleration suggests that recent operational performance, driven by the expanding share of smoke-free revenues (42% of Q2FY26 net revenues), is generating sufficient cash flow to support higher-than-historical payout increases while maintaining financial flexibility.
How might the accelerating 8.8% dividend growth rate impact Philip Morris's ability to fund future R&D for next-generation smoke-free technologies?
What are the potential risks to PMI's cash flow stability if regulatory hurdles slow the adoption of smoke-free products in key international markets?
How could the increasing dominance of smoke-free revenues (42% in Q2) affect Philip Morris's valuation multiples compared to traditional tobacco peers?

































